Antiapicoplast and gametocytocidal screening to identify the mechanisms of action of compounds within the malaria box

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 811-819

  Bowman, Jessica D ^a   Merino, Emilio F ^a   Brooks, Carrie F ^b   Striepen, Boris ^b   Carlier, Paul R ^a   Cassera, Maria B ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; DOXYCYCLINE; FOSMIDOMYCIN; MMV 008138; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; APICOMPLEXAN LIFE CYCLE STAGE; APICOPLAST; ARTICLE; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG DETERMINATION; DRUG SCREENING; DRUG SENSITIVITY; GAMETOCYTE; GROWTH INHIBITION; IC 50; IN VITRO STUDY; MALARIA; MALARIA BOX; NONHUMAN; PHENOTYPE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; TOXOPLASMA GONDII;

ANTIMALARIALS; APICOPLASTS; CARBOLINES; DRUG DISCOVERY; ERYTHROCYTES; FOSFOMYCIN; HEMITERPENES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; LIFE CYCLE STAGES; OLIGOPEPTIDES; ORGANOPHOSPHORUS COMPOUNDS; PIPECOLIC ACIDS; PLASMODIUM FALCIPARUM; SMALL MOLECULE LIBRARIES;

EID: 84893487091     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01500-13     Document Type: Article

References (55)

1. Burrows JN. 2012. Antimalarial drug discovery: where next? Future Med. Chem. 4:2233-2235. http://dx.doi.org/10.4155/fmc.12.189.
2. Spangenberg T, Burrows JN, Kowalczyk P, McDonald S, Wells TNC, Willis P. 2013. The open access Malaria Box: a drug discovery catalyst for neglected diseases. PLoS One 8:e62906. http://dx.doi.org/10.1371/journal.pone.0062906.
3. Guiguemde WA, Shelat AA, Garcia-Bustos JF, Diagana TT, Gamo FJ, Guy RK. 2012. Global phenotypic screening for antimalarials. Chem. Biol. 19:116-129. http://dx.doi.org/10.1016/j.chembiol.2012.01.004.
4. Goodman CD, McFadden GI. 2013. Targeting apicoplasts in malaria parasites. Expert Opin. Ther. Targets 17:167-177. http://dx.doi.org/10.1517/ 14728222.2013.739158.
5. van Dooren GG, Striepen B. 2013. The algal past and parasite present of the apicoplast. Annu. Rev. Microbiol. 67:271-289. http://dx.doi.org/10.1146/ annurev-micro-092412-155741.
6. Odom AR, Van Voorhis WC. 2010. Functional genetic analysis of the Plasmodium falciparum deoxyxylulose 5-phosphate reductoisomerase gene. Mol. Biochem. Parasitol. 170:108-111. http://dx.doi.org/10.1016/j.molbiopara.2009.12. 001.
7. Nair SC, Brooks CF, Goodman CD, Sturm A, McFadden GI, Sundriyal S, Anglin JL, Song Y, Moreno SN, Striepen B. 2011. Apicoplast isoprenoid precursor synthesis and the molecular basis of fosmidomycin resistance in Toxoplasma gondii. J. Exp. Med. 208:1547-1559. http://dx.doi.org/10.1084/jem.20110039.
8. Yeh E, DeRisi JL. 2011. Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage Plasmodium falciparum. PLoS Biol. 9:e1001138. http://dx.doi.org/10.1371/journal.pbio.1001138.
9. Wittlin S, Ekland E, Craft JC, Lotharius J, Bathurst I, Fidock DA, Fernandes P. 2012. In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium species. Antimicrob. Agents Chemother. 56: 703-707. http://dx.doi.org/10.1128/AAC.05039-11.
10. Dahl EL, Rosenthal PJ. 2007. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob. Agents Chemother. 51:3485-3490. http://dx.doi.org/10.1128/AAC.00527-07.
11. Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ. 2006. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob. Agents Chemother. 50:3124-3131. http://dx.doi.org/10.1128/AAC.00394-06.
12. Goodman CD, Su V, McFadden GI. 2007. The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. 152:181-191. http://dx.doi.org/10.1016/j.molbiopara.2007.01.005.
13. Aminake MN, Schoof S, Sologub L, Leubner M, Kirschner M, Arndt HD, Pradel G. 2011. Thiostrepton and derivatives exhibit antimalarial and gametocytocidal activity by dually targeting parasite proteasome and apicoplast. Antimicrob. Agents Chemother. 55:1338-1348. http://dx.doi.org/10.1128/AAC.01096-10.
14. Rathore S, Sinha D, Asad M, Bottcher T, Afrin F, Chauhan VS, Gupta D, Sieber SA, Mohmmed A. 2010. A cyanobacterial serine protease of Plasmodium falciparum is targeted to the apicoplast and plays an important role in its growth and development. Mol. Microbiol. 77:873-890. http://dx.doi.org/10.1111/j. 1365-2958.2010.07251.x.
15. Fichera ME, Roos DS. 1997. A plastid organelle as a drug target in apicomplexan parasites. Nature 390:407-409. http://dx.doi.org/10.1038/37132.
16. Dahl EL, Rosenthal PJ. 2008. Apicoplast translation, transcription and genome replication: targets for antimalarial antibiotics. Trends Parasitol. 24:279-284. http://dx.doi.org/10.1016/j.pt.2008.03.007.
17. Cassera MB, Gozzo FC, D'Alexandri FL, Merino EF, del Portillo HA, Peres VJ, Almeida IC, Eberlin MN, Wunderlich G, Wiesner J, Jomaa H, Kimura EA, Katzin AM. 2004. The methylerythritol phosphate pathway is functionally active in all intraerythrocytic stages of Plasmodium falciparum. J. Biol. Chem. 279:51749-51759. http://dx.doi.org/10.1074/jbc.M408360200.
18. Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, Hintz M, Turbachova I, Eberl M, Zeidler J, Lichtenthaler HK, Soldati D, Beck E. 1999. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 285:1573-1576. http://dx.doi.org/10.1126/science. 285.5433.1573.
19. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D. 2012. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 9:e1001169. http://dx.doi.org/10.1371/journal.pmed.1001169.
20. Peatey CL, Leroy D, Gardiner DL, Trenholme KR. 2012. Anti-malarial drugs: how effective are they against Plasmodium falciparum gametocytes? Malar. J. 11:34. http://dx.doi.org/10.1186/1475-2875-11-34.
21. Waller RF, Reed MB, Cowman AF, McFadden GI. 2000. Protein trafficking to the plastid of Plasmodium falciparum is via the secretory pathway. EMBOJ. 19:1794-1802. http://dx.doi.org/10.1093/emboj/19.8.1794.
22. Dharia NV, Sidhu AB, Cassera MB, Westenberger SJ, Bopp SE, Eastman RT, Plouffe D, Batalov S, Park DJ, Volkman SK, Wirth DF, Zhou Y, Fidock DA, Winzeler EA. 2009. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol. 10:R21. http://dx.doi.org/10.1186/gb-2009-10-2-r21.
23. Harinantenaina L, Bowman JD, Brodie PJ, Slebodnick C, Callmander MW, Rakotobe E, Randrianaivo R, Rasamison VE, Gorka A, Roepe PD, Cassera MB, Kingston DG. 2013. Antiproliferative and antiplasmodial dimeric phloroglucinols from Mallotus oppositifolius from the Madagascar dry forest. J. Nat. Prod. 76:388-393. http://dx.doi.org/10.1021/np300750q.
24. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M. 2004. Simple and inexpensive fluorescence-based technique for highthroughput antimalarial drug screening. Antimicrob. Agents Chemother. 48:1803-1806. http://dx.doi.org/10.1128/AAC.48.5.1803-1806.2004.
25. Gubbels MJ, Li C, Striepen B. 2003. High-throughput growth assay for Toxoplasma gondii using yellow fluorescent protein. Antimicrob. Agents Chemother. 47:309-316. http://dx.doi.org/10.1128/AAC.47.1.309-316.2003.
26. MacRae JI, Dixon MW, Dearnley MK, Chua HH, Chambers JM, Kenny S, Bottova I, Tilley L, McConville MJ. 2013. Mitochondrial metabolism of sexual and asexual blood stages of the malaria parasite Plasmodium falciparum.BMCBiol. 11:67. http://dx.doi.org/10.1186/1741-7007-11-67.
27. Tanaka TQ, Williamson KC. 2011. A malaria gametocytocidal assay using oxidoreduction indicator, alamarBlue. Mol. Biochem. Parasitol. 177:160-163. http://dx.doi.org/10.1016/j.molbiopara.2011.02.005.
28. Czesny B, Goshu S, Cook JL, Williamson KC. 2009. The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity. Antimicrob. Agents Chemother. 53:4080-4085. http://dx.doi.org/10.1128/AAC.00088- 09.
29. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR, Peishoff CE, Cardon LR, Garcia-Bustos JF. 2010. Thousands of chemical starting points for antimalarial lead identification. Nature 465:305-310. http://dx.doi.org/10.1038/nature09107.
30. Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MC, McNamara CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA. 2011. Imaging of Plasmodium liver stages to drive nextgeneration antimalarial drug discovery. Science 334:1372-1377. http://dx.doi.org/10.1126/science.1211936.
31. Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, Nagle A, Adrian F, Matzen JT, Anderson P, Nam TG, Gray NS, Chatterjee A, Janes J, Yan SF, Trager R, Caldwell JS, Schultz PG, Zhou Y, Winzeler EA. 2008. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc. Natl. Acad. Sci. U. S. A. 105:9059-9064. http://dx.doi.org/10.1073/pnas.0802982105.
32. Cassera MB, Merino EF, Peres VJ, Kimura EA, Wunderlich G, Katzin AM. 2007. Effect of fosmidomycin on metabolic and transcript profiles of the methylerythritol phosphate pathway in Plasmodium falciparum. Mem. Inst. Oswaldo Cruz 102:377-383. http://dx.doi.org/10.1590/S0074-02762007000300019.
33. Ralph SA, Van Dooren GG, Waller RF, Crawford MJ, Fraunholz MJ, Foth BJ, Tonkin CJ, Roos DS, McFadden GI. 2004. Tropical infectious diseases: metabolic maps and functions of the Plasmodium falciparum apicoplast. Nat. Rev. Microbiol. 2:203-216. http://dx.doi.org/10.1038/nrmicro843.
34. Lim L, McFadden GI. 2010. The evolution, metabolism and functions of the apicoplast. Philos. Trans. R. Soc. Lond. B Biol. Sci. 365:749-763. http://dx.doi.org/10.1098/rstb.2009.0273.
35. van der Meer JY, Hirsch AK. 2012. The isoprenoid-precursor dependence of Plasmodium spp. Nat. Prod. Rep. 29:721-728. http://dx.doi.org/10.1039/ c2np20013a.
36. Okamoto N, Spurck TP, Goodman CD, McFadden GI. 2009. Apicoplast and mitochondrion in gametocytogenesis of Plasmodium falciparum. Eukaryot. Cell 8:128-132. http://dx.doi.org/10.1128/EC.00267-08.
37. Missinou MA, Borrmann S, Schindler A, Issifou S, Adegnika AA, Matsiegui PB, Binder R, Lell B, Wiesner J, Baranek T, Jomaa H, Kremsner PG. 2002. Fosmidomycin for malaria. Lancet 360:1941-1942. http://dx.doi.org/10.1016/S0140- 6736(02)11860-5.
38. Wiesner J, Borrmann S, Jomaa H. 2003. Fosmidomycin for the treatment of malaria. Parasitol. Res. 90(Suppl.):S71-76. http://dx.doi.org/10.1007/s00436- 002-0770-9.
39. Wiesner J, Henschker D, Hutchinson DB, Beck E, Jomaa H. 2002. In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrob. Agents Chemother. 46:2889-2894. http://dx.doi.org/10. 1128/AAC.46.9.2889-2894.2002.
40. Borrmann S, Adegnika AA, Matsiegui PB, Issifou S, Schindler A, Mawili-Mboumba DP, Baranek T, Wiesner J, Jomaa H, Kremsner PG. 2004. Fosmidomycin-clindamycin for Plasmodium falciparum infections in African children. J. Infect. Dis. 189:901-908. http://dx.doi.org/10.1086/381785.
41. Borrmann S, Adegnika AA, Moussavou F, Oyakhirome S, Esser G, Matsiegui PB, Ramharter M, Lundgren I, Kombila M, Issifou S, Hutchinson D, Wiesner J, Jomaa H, Kremsner PG. 2005. Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 49: 3749-3754. http://dx.doi.org/10.1128/AAC.49.9.3749-3754.2005.
42. Borrmann S, Issifou S, Esser G, Adegnika AA, Ramharter M, Matsiegui PB, Oyakhirome S, Mawili-Mboumba DP, Missinou MA, Kun JF, Jomaa H, Kremsner PG. 2004. Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J. Infect. Dis. 190:1534-1540. http://dx.doi.org/10.1086/424603.
43. Na-Bangchang K, Ruengweerayut R, Karbwang J, Chauemung A, Hutchinson D. 2007. Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria. Malar. J. 6:70. http://dx.doi.org/10.1186/1475-2875-6-70.
44. Spillman NJ, Allen RJ, McNamara CW, Yeung BK, Winzeler EA, Diagana TT, Kirk K. 2013. Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe 13:227-237. http://dx.doi.org/10.1016/j.chom. 2012.12.006.
45. van Pelt-Koops JC, Pett HE, Graumans W, van der Vegte-Bolmer M, van Gemert GJ, Rottmann M, Yeung BK, Diagana TT, Sauerwein RW. 2012. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector. Antimicrob. Agents Chemother. 56:3544-3548. http://dx.doi.org/10.1128/AAC.06377- 11.
46. Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, Gonzalez-Paez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT. 2010. Spiroindolones, a potent compound class for the treatment of malaria. Science 329:1175-1180. http://dx.doi.org/10.1126/science.1193225.
47. Yeung BK, Zou B, Rottmann M, Lakshminarayana SB, Ang SH, Leong SY, Tan J, Wong J, Keller-Maerki S, Fischli C, Goh A, Schmitt EK, Krastel P, Francotte E, Kuhen K, Plouffe D, Henson K, Wagner T, Winzeler EA, Petersen F, Brun R, Dartois V, Diagana TT, Keller TH. 2010. Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J. Med. Chem. 53:5155-5164. http://dx.doi.org/10.1021/ jm100410f.
48. Cao R, Peng W, Wang Z, Xu A. 2007. beta-Carboline alkaloids: biochemical and pharmacological functions. Curr. Med. Chem. 14:479-500. http://dx.doi.org/ 10.2174/092986707779940998.
49. Dechy-Cabaret O, Benoit-Vical F. 2012. Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate. J. Med. Chem. 55:10328-10344. http://dx.doi.org/10.1021/jm3005898.
50. Valdes AF. 2011. Acridine and acridinones: old and new structures with antimalarial activity. Open Med. Chem. J. 5:11-20. http://dx.doi.org/10.2174/ 1874104501105010011.
51. Hoglund IP, Silver S, Engstrom MT, Salo H, Tauber A, Kyyronen HK, Saarenketo P, Hoffren AM, Kokko K, Pohjanoksa K, Sallinen J, Savola JM, Wurster S, Kallatsa OA. 2006. Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J. Med. Chem. 49:6351-6363. http://dx.doi.org/10.1021/jm060262x.
52. Carlier PR, Han YF, Chow ES, Li CP, Wang H, Lieu TX, Wong HS, Pang YP. 1999. Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Bioorg. Med. Chem. 7:351-357.
53. Pou S, Winter RW, Nilsen A, Kelly JX, Li Y, Doggett JS, Riscoe EW, Wegmann KW, Hinrichs DJ, Riscoe MK. 2012. Sontochin as a guide to the development of drugs against chloroquine-resistant malaria. Antimicrob. Agents Chemother. 56:3475-3480. http://dx.doi.org/10.1128/AAC.00100-12.
54. Covell G, Coatney GR, Field JW, Singh J. 1955. Chemotherapy of malaria. Monogr. Ser. World Health Organ. 27:1-123.
55. Powell RD, Tigertt WD. 1968. Drug resistance of parasites causing human malaria. Annu. Rev. Med. 19:81-102. http://dx.doi.org/10.1146/annurev.me.19. 020168.000501.